Cinchocaine and hydrocortisone rectal
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Rectal formulations containing cinchocaine hydrochloride and hydrocortisone.
Drugs List
Therapeutic Indications
Uses
Haemorrhoids - external
Haemorrhoids - internal
Pruritus ani
Dosage
Adults
Ointment
Apply twice daily (morning and evening) and after each bowel movement to the painful or pruritic area for no more than 7 days.
Suppository
1 suppository to be inserted twice daily (morning and evening) and after each bowel movement for no more than 7 days.
Children
Ointment
Children aged 12 to 18 years
Apply twice daily (morning and evening) and after bowel movement to the painful area, externally or by rectum for no more than 7 days.
Children aged 1 month to 12 years (unlicensed)
Apply twice daily (morning and evening) and after bowel movement to the painful area, externally or by rectum for no more than 7 days.
Suppositories
Children aged 12 to 18 years
1 suppository to be inserted twice daily (morning and evening) and after each bowel movement for no more than 7 days.
Administration
For rectal administration.
Suppositories and ointment may be used separately or concurrently.
Contraindications
Administration site infection
Hypersensitivity to lanolin
Tuberculosis
Precautions and Warnings
Children under 12 years
Breastfeeding
Pregnancy
May mask symptoms or signs of infections
Not all available brands are licensed for use in children under 12 years
Not all formulations are licensed for all uses
Some formulations contain lanolin
Avoid use of occlusive dressings - increased risk of sensitivity reactions
If visual disturbances occur, perform ophthalmic evaluation
May cause sensitisation
Prolonged use may cause atrophic skin changes
Risk of adrenal suppression secondary to absorption of steroid
Pregnancy: Avoid excessive or unduly prolonged administration
Maximum treatment 7 days unless on doctor's advice
Only recommended for short term use
Advise patient to consult a doctor if symptoms persist despite treatment
Pregnancy and Lactation
Pregnancy
Use cinchocaine and hydrocortisone with caution during pregnancy.
The manufacturers advise that cinchocaine and hydrocortisone may be used with caution during pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There is inadequate evidence of safety in human pregnancy. There may be a very small risk of such effects in the human foetus. Topical steroids should not be used excessively in pregnancy.
Lactation
Use cinchocaine and hydrocortisone with caution during breastfeeding.
The manufacturers advise that cinchocaine and hydrocortisone may be used with caution during breastfeeding. Hydrocortisone may pass into human breast milk. Maternal use rectally with an ointment or by suppository for a short period of time poses very little risk to the breastfed infant.
Side Effects
Adrenal suppression
Anal irritation
Blurred vision
Chorioretinopathy
Contact sensitisation
Rash
Urticaria
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: November 2019
Reference Sources
Summary of Product Characteristics: Proctosedyl Ointment. Aventis Pharma Ltd. Revised September 2019.
Summary of Product Characteristics: Proctosedyl Suppositories. Aventis Pharma Ltd. Revised September 2019.
Summary of Product Characteristics: Uniroid-HC Ointment. Chemidex Pharma Ltd. Revised April 2015.
Summary of Product Characteristics: Uniroid-HC Suppositories. Chemidex Pharma Ltd. Revised September 2018.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 14 November 2019
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.